Samrat Pharmachem Limited (BOM:530125)
India · Delayed Price · Currency is INR 242.70
+5.65 (2.38%)
At close: Aug 21, 2026
Samrat Pharmachem Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Operating Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | -33.12 | 71.12 | 21.63 | 166.31 | 171.85 |
Depreciation & Amortization | 7.2 | 6.53 | 6.46 | 6.42 | 5.94 |
Other Amortization | - | 0.02 | 0.01 | 0.01 | 0.01 |
Loss (Gain) From Sale of Assets | 0.18 | 0.95 | -0.18 | - | 0.23 |
Loss (Gain) From Sale of Investments | -3.07 | -4.05 | -9.87 | -0.23 | -0.08 |
Provision & Write-off of Bad Debts | - | - | - | - | 0.23 |
Other Operating Activities | -5.42 | 16.24 | -22.23 | -25.7 | 54.35 |
Change in Accounts Receivable | 54.98 | 127.45 | -176.06 | -80.99 | -106.09 |
Change in Inventory | -56.17 | -173.28 | 118.51 | -201.12 | -10.16 |
Change in Accounts Payable | 41.03 | -91.07 | 157.88 | 84.89 | 57.33 |
Change in Other Net Operating Assets | 83.19 | -54.81 | -2.03 | -43.96 | 1.13 |
Operating Cash Flow | 88.8 | -100.91 | 94.12 | -94.37 | 174.74 |
Operating Cash Flow Growth | - | - | - | - | 264.22% |
Investing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Capital Expenditures | -30.96 | -5.07 | -6.67 | -14.59 | -12.76 |
Sale of Property, Plant & Equipment | - | - | 0.18 | 0.99 | 0.76 |
Investment in Securities | 2.35 | 1.33 | -0.62 | -18.45 | -0.02 |
Other Investing Activities | 2.87 | 3.69 | 3.05 | 2 | 1.38 |
Investing Cash Flow | -25.74 | -0.05 | -4.06 | -30.05 | -10.64 |
Financing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Short-Term Debt Issued | 7.92 | 14.6 | - | 111.4 | - |
Total Debt Issued | 7.92 | 14.6 | - | 111.4 | - |
Short-Term Debt Repaid | - | - | -102.05 | - | -12.74 |
Total Debt Repaid | - | - | -102.05 | - | -12.74 |
Net Debt Issued (Repaid) | 7.92 | 14.6 | -102.05 | 111.4 | -12.74 |
Common Dividends Paid | -3.09 | -3.09 | -3.09 | -3.09 | - |
Other Financing Activities | -9.55 | -6.74 | -6.87 | -12.32 | -6.75 |
Financing Cash Flow | -4.72 | 4.77 | -112.01 | 95.99 | -19.49 |
Net Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Cash Flow | 58.34 | -96.19 | -21.95 | -28.43 | 144.62 |
Free Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 57.84 | -105.99 | 87.45 | -108.96 | 161.98 |
Free Cash Flow Growth | - | - | - | - | 682.87% |
Free Cash Flow Margin | 2.00% | -3.71% | 3.10% | -3.51% | 7.30% |
Free Cash Flow Per Share | 18.72 | -34.30 | 28.30 | -35.27 | 52.42 |
Levered Free Cash Flow | 62.2 | -124.04 | 85.05 | -126.9 | 134.99 |
Unlevered Free Cash Flow | 68.17 | -121 | 88.51 | -121.09 | 137.27 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash Interest Paid | 9.55 | 6.74 | 6.87 | 12.32 | 6.75 |
Cash Income Tax Paid | 15.3 | 14.52 | 29.66 | 95 | 15.34 |
Change in Working Capital | 123.02 | -191.72 | 98.31 | -241.18 | -57.79 |